300238 Guanhao Biotech
- 10.07
- +0.13+1.31%
Guanhao Biotech News
Guanhao Biology (300238.SZ): Does not involve synthetic biology business or related research
Gelonghui May 9 丨 Guanhao Biology (300238.SZ) announced the stock price change announcement. The company paid attention to some media, stock bars and other platforms to discuss synthetic biology and related hot concepts. Currently, the company is not involved in synthetic biology business or related research.
Guanhao Biology (300238.SZ): The core business is the three major business segments of materials, pharmaceuticals, and cells
Gelonghui, May 8 | Guanhao Biology (300238.SZ) said on the investor interactive platform that the company's core business is the three major business segments: materials, pharmaceuticals, and cells. The main products in the field of materials include biotype dural (spine) membrane patches, B-type cerebral (spine) membrane patches, thoracic surgical repair films, sterile biological wound protection films, and Ario breast patches, which can be widely used in neurosurgery, thoracic surgery, dermatology, orthopedics, plastic surgery, etc. Benvermide, the main product in the pharmaceutical industry, can treat inflammatory and autoimmune diseases such as psoriasis and atopic dermatitis. The cell field mainly includes cell storage and cellular cartilage treatment
Guan Hao Biology (300238.SZ): Currently, the company is not involved in synthetic biology-related research
Gelonghui May 8 丨 Guanhao Biology (300238.SZ) said on the investor interactive platform that currently the company is not involved in synthetic biology-related research.
The controlling shareholder of Guanhao Biology (300238.SZ) pledges 14.65 million shares
Guanhao Biology (300238.SZ) announced that the company recently received Guangdong Zhiguang Biotechnology Co., Ltd., the controlling shareholder of the company...
Guanhao Biology (300238.SZ): As of March 20, 2024, the total number of shareholders of the company was 31,042
Gelonghui March 21丨Guanhao Biotech (300238.SZ) said on the investor interactive platform that as of March 20, 2024, the total number of shareholders of the company was 31,042.
Optimistic Investors Push Guanhao Biotech Co.,Ltd. (SZSE:300238) Shares Up 26% But Growth Is Lacking
Those holding Guanhao Biotech Co.,Ltd. (SZSE:300238) shares would be relieved that the share price has rebounded 26% in the last thirty days, but it needs to keep going to repair the recent damage it
Guan Hao Biology (300238.SZ): No plans to participate in the brain-computer interface conference
Gelonghui March 12 丨 Guanhao Biology (300238.SZ) said on the investor interactive platform that the company has no plans to participate in the brain-computer interface conference yet.
Guanhao Biotech (300238.SZ): 2023 net profit of 31.058 million yuan reversed year-on-year losses
Gelonghui March 5 | Guanhao Biotech (300238.SZ) released its 2023 annual report. In 2023, the company achieved operating income of 404 million yuan, an increase of 7.13% over the previous year; net profit attributable to shareholders of listed companies was 31.058 million yuan, which turned a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 305.554 million yuan; and basic earnings per share were 0.12 yuan.
Express News | China Brain Stocks Up After Report on Musk's Neuralink Patient
Guanhao Biology (300238.SZ): Received a warning letter from Guangdong Securities Regulatory Bureau
Gelonghui, Feb. 5, 丨 Guanhao Biotech (300238.SZ) announced that the company recently received the “Decision on Measures to Issue Warning Letters against Guanhao Biotechnology Co., Ltd., Zhang Yongming, Wang Xinzhi, and Zhao Junhui” ([2023] No. 177) (hereinafter referred to as the “Warning Letter”) issued by the Guangdong Regulatory Bureau (hereinafter referred to as the “Guangdong Securities Regulatory Bureau”) of the China Securities Regulatory Commission. According to the provisions of Article 52 of the “Administrative Measures on Information Disclosure of Listed Companies”, our bureau decided to take administrative supervision measures to issue warning letters against Guan Hao Biotech, Zhang Yongming, Wang Xinzhi, and Zhao Junhui. You should carefully absorb
Guanhao Biology (300238.SZ): Expected net profit of 28 million yuan to 33 million yuan in 2023 to reverse the year-on-year loss
On January 25, Gelonghui | Guanhao Biotech (300238.SZ) announced that it expects net profit of 28 million yuan to 33 million yuan in 2023, reversing losses year-on-year, and deducting non-net profit of 23.85 million yuan to 28.85 million yuan, reversing year-on-year losses. During the reporting period, the company actively developed the market. The company's revenue for some membrane products, benvilimod cream, and cell technology services all increased compared to the same period last year. The company estimates that the impact of non-recurring profit and loss in 2023 on net profit attributable to shareholders of listed companies is approximately RMB 4.15 million.
Guanhao Biology (300238.SZ): Appoints Zhang Yongming as the company's general manager
Gelonghui, January 14, 丨 Guanhao Biology (300238.SZ) issued an announcement. The board of directors recently received the resignation report submitted by Wang Xinzhi. Wang Xinzhi applied to resign as general manager of the company due to his personal age. After his resignation, Wang Xinzhi will continue to serve as Vice Chairman of the Company's 6th Board of Directors and a member of the Strategy Committee. Wang Xinzhi's resignation report took effect on the day it was delivered to the board of directors, and his resignation will not adversely affect the company's daily operations. The company held the fifth meeting of the sixth board of directors on January 12, 2024 to review and pass the “Proposal on the Appointment of the Company's General Manager”. The board of directors proposed by the chairman
Guanhao Biology (300238.SZ): As of January 10, 2024, the total number of shareholders of the company was 30,725
Gelonghui January 12 | Guanhao Biotech (300238.SZ) said on the investor interactive platform that as of January 10, 2024, the total number of shareholders of the company was 30,725.
Guanhao Biotech (300238.SZ): Controlling shareholder dissolves 5.53% of company shares
Guanhao Biotech (300238.SZ) announced that Guangdong Zhiguang Biotechnology Co., Ltd., the controlling shareholder of the company (hereinafter referred to as...
Guan Hao Biology (300238.SZ): No research related to gene editing has been involved
On November 20, Gelonghui, Guanhao Biotech (300238.SZ) stated on the investor interactive platform that the company has not yet been involved in research related to gene editing.
Guanhao Biology (300238.SZ): Products such as biotype dura (dorsal) membrane patches, type B dura patches, etc. are mainly used in neurosurgery
Gelonghui November 14|Guanhao Biology (300238.SZ) stated on the investor interactive platform that the company's products, such as biotype hard brain (spine) patch and type B durum patch, are mainly used in neurosurgery.
Guanhao Biology (300238.SZ): The product, Verimod, can treat inflammatory and autoimmune diseases, such as psoriasis, atopic dermatitis, etc.
Gelonghui November 14|Guanhao Biotech (300238.SZ) stated on the investor interactive platform that the company's main product in the pharmaceutical field, benvermod, can treat inflammatory and autoimmune diseases, such as psoriasis and atopic dermatitis.
Guanhao Biotech (300238.SZ): As of November 10, 2023, the total number of shareholders in the company is 33213
Gelonghui November 14|Guanhao Biotech (300238.SZ) stated on the investor interactive platform that as of November 10, 2023, the total number of shareholders in the company was 3,3213.
Guanhao Biology (300238.SZ): The biological artificial liver project carried out is currently in the scientific research and clinical research stage
Gelonghui November 9: Some investors asked Guanhao Biotech (300238.SZ) on the investor interactive platform, “How is the company's biotype artificial liver research and development progressing?” The company replied that the biological artificial liver project carried out by the company is currently in the scientific research and clinical research stage.
Guanhao BiotechLtd (SZSE:300238) Delivers Shareholders Notable 7.1% CAGR Over 5 Years, Surging 12% in the Last Week Alone
Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking involves risks (and requires diversification) it can also provide excess returns
Analysis
Price Target
No Data
